Literature DB >> 28815428

The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Paul LaPenna1, Laura M Tormoehlen2,3.   

Abstract

Epilepsy is a neurologic disorder affecting approximately 50 million people worldwide, or about 0.7% of the population [1]. Thus, the use of anticonvulsant drugs in the treatment of epilepsy is common and widespread. There are three generations of anticonvulsant drugs, categorized by the year in which they were developed and released. The aim of this review is to discuss the pharmacokinetics, drug-drug interactions, and adverse events of the third generation of anticonvulsant drugs. Where available, overdose data will be included. The pharmacokinetic properties of third-generation anticonvulsant drugs include relatively fewer drug-drug interactions, as well as several unique and life-threatening adverse events. Overdose data are limited, so thorough review of adverse events and knowledge of drug mechanism will guide expectant management of future overdose cases. Reporting of these cases as they occur will be necessary to further clarify toxicity of these drugs.

Entities:  

Keywords:  Anticonvulsants; Drug overdose; Epilepsy; Pharmacokinetics; Poisoning

Mesh:

Substances:

Year:  2017        PMID: 28815428      PMCID: PMC5711757          DOI: 10.1007/s13181-017-0626-4

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  159 in total

1.  Sensorineural hearing loss: a reversible effect of vigabatrin.

Authors:  E Papadeas; P Polychronopoulos; P Papathanasopoulos; C Frimas; N Pharmakakis; C Paschalis
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

Review 2.  The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.

Authors:  Neil Brickel; Paul Gandhi; Kevan VanLandingham; Janet Hammond; Sarah DeRossett
Journal:  Epilepsia       Date:  2012-03-16       Impact factor: 5.864

3.  Lacosamide-induced acute pancreatitis with positive rechallenge test.

Authors:  Adolfo del Val Antoñana; Michel Blé Caso; Maria D Higón Ballester; Juan A Ortuño Cortés
Journal:  J Clin Gastroenterol       Date:  2014-08       Impact factor: 3.062

4.  Psychiatric adverse events during vigabatrin therapy.

Authors:  D F Levinson; O Devinsky
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

5.  Evolution of visual field loss over ten years in individuals taking vigabatrin.

Authors:  Lisa M Clayton; William M Stern; William D Newman; Josemir W Sander; James Acheson; Sanjay M Sisodiya
Journal:  Epilepsy Res       Date:  2013-03-28       Impact factor: 3.045

6.  A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.

Authors:  Mark Naccarato; Deborah Yoong; Colin Kovacs; Kevin Gough
Journal:  Antivir Ther       Date:  2011-11-04

7.  Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.

Authors:  I Rektor; G L Krauss; M Bar; V Biton; J A Klapper; N Vaiciene-Magistris; R Kuba; D Squillacote; M Gee; D Kumar
Journal:  Acta Neurol Scand       Date:  2012-08-23       Impact factor: 3.209

8.  Sinus node dysfunction: an adverse effect of lacosamide.

Authors:  Suganthi Chinnasami; Chaturbhuj Rathore; John S Duncan
Journal:  Epilepsia       Date:  2013-01-29       Impact factor: 5.864

9.  Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.

Authors:  Reetta Kälviäinen; Pierre Genton; Eva Andermann; Frederick Andermann; Adriana Magaudda; Steven J Frucht; Anne-Françoise Schlit; Danielle Gerard; Christine de la Loge; Philipp von Rosenstiel
Journal:  Epilepsia       Date:  2015-12-15       Impact factor: 5.864

Review 10.  Profile of brivaracetam and its potential in the treatment of epilepsy.

Authors:  Edoardo Ferlazzo; Emilio Russo; Laura Mumoli; Chiara Sueri; Sara Gasparini; Caterina Palleria; Angelo Labate; Antonio Gambardella; Giovambattista De Sarro; Umberto Aguglia
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-30       Impact factor: 2.570

View more
  8 in total

Review 1.  Exploring the multifaceted neuroprotective actions of Emblica officinalis (Amla): a review.

Authors:  Ibraheem Husain; Saima Zameer; Tushar Madaan; Akram Minhaj; Wasim Ahmad; Asif Iqubaal; Abuzer Ali; Abul Kalam Najmi
Journal:  Metab Brain Dis       Date:  2019-03-08       Impact factor: 3.584

2.  Transcriptomic and proteomic profiling of glial versus neuronal Dube3a overexpression reveals common molecular changes in gliopathic epilepsies.

Authors:  Kevin A Hope; Daniel Johnson; P Winston Miller; Daniel Lopez-Ferrer; David Kakhniashvili; Lawrence T Reiter
Journal:  Neurobiol Dis       Date:  2020-04-25       Impact factor: 5.996

3.  Design, synthesis and biological evaluation of N-substituted α-hydroxyimides and 1,2,3-oxathiazolidine-4-one-2,2-dioxides with anticonvulsant activity.

Authors:  Laureano L Sabatier; Pablo H Palestro; Andrea V Enrique; Valentina Pastore; María L Sbaraglini; Pedro Martín; Luciana Gavernet
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

Review 4.  Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.

Authors:  Manuela Gernert; Malte Feja
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

Review 5.  Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges.

Authors:  Lorena Bonilla; Gerard Esteruelas; Miren Ettcheto; Marta Espina; María Luisa García; Antoni Camins; Eliana B Souto; Amanda Cano; Elena Sánchez-López
Journal:  Epilepsia Open       Date:  2021-12-13

6.  Truncal Ataxia and Prolonged Coma in an Exploratory Pediatric Perampanel Ingestion.

Authors:  Diana Dean; Karla D Passalacqua; Bram Dolcourt
Journal:  J Med Toxicol       Date:  2021-06-01

7.  Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study.

Authors:  Mark Cook; Michael Murphy; Kristian Bulluss; Wendyl D'Souza; Chris Plummer; Emma Priest; Catherine Williams; Ashwini Sharan; Robert Fisher; Sharon Pincus; Eric Distad; Tom Anchordoquy; Dan Abrams
Journal:  EClinicalMedicine       Date:  2020-05-03

Review 8.  Drug Delivery Challenges in Brain Disorders across the Blood-Brain Barrier: Novel Methods and Future Considerations for Improved Therapy.

Authors:  Aneesha Achar; Rosemary Myers; Chaitali Ghosh
Journal:  Biomedicines       Date:  2021-12-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.